Targeted treatment for triple negative breast cancer using advanced antibody drug conjugates.
Official title: Proteasome Inhibitor-Loaded Antibody Drug Conjugates with High Drug Loading For Targeted Treatment of Triple Negative Breast Cancers
Funded at Window Therapeutics, INC. · NIH-10822628 · Data updated 2026-11-12
This study is exploring a new treatment for triple negative breast cancer that uses special drugs designed to target cancer cells directly, which could make the treatment more effective and cause fewer side effects for patients who haven't had success with other therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Window Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Dorchester, UNITED STATES) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $299,999 |
| NIH project number | 1R43CA287804-01 |
| Project ID | NIH-10822628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have not responded to standard treatments.
✕Less likely to help
Patients with other types of breast cancer or those who have already received multiple lines of treatment may not benefit from this research.
What this research studies
This research focuses on developing a new type of treatment for triple negative breast cancer (TNBC) using antibody drug conjugates (ADCs) that are loaded with proteasome inhibitors. The approach aims to deliver these drugs directly to cancer cells, minimizing side effects and enhancing effectiveness. By utilizing a novel platform that allows for higher drug loading than current FDA-approved ADCs, the research seeks to improve treatment outcomes for patients who have not responded to existing therapies. The project will involve synthesizing and testing these ADCs in preclinical models to evaluate their efficacy and safety.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients with triple negative breast cancer.
How similar studies have gone: While proteasome inhibitors have shown success in treating multiple myeloma, their application in solid tumors like TNBC is still largely untested, making this research a novel approach.
Where this research is happening
-
Window Therapeutics, INC.
Dorchester, United States Active
Researchers
- Principal investigator: Jiang, Yivan — Window Therapeutics, INC.
- Study coordinator: Jiang, Yivan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.